|
15 Jan 2021 |
Imfinzi approved in the EU for less-frequent, fixed-dose use in unresectable non-small cell lung cancer
|
|
14 Jan 2021 |
Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie
|
|
14 Jan 2021 |
Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19
|
|
13 Jan 2021 |
Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid Tumors
|
|
13 Jan 2021 |
LEO Pharma initiates head-to-head study to evaluate brodalumab vs. guselkumab in adult patients with moderate-to-severe psoriasis who have inadequate response to ustekinumab
|
|
13 Jan 2021 |
Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59
|
|
13 Jan 2021 |
UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer
|
|
12 Jan 2021 |
Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
|
|
12 Jan 2021 |
DiosCURE to Develop Highly Specific Single-Chain Antibodies Against SARS-CoV-2, Lead Candidates Described in Science Publication
|
|
12 Jan 2021 |
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
|
|
12 Jan 2021 |
AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development
|
|
12 Jan 2021 |
Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
|
|
11 Jan 2021 |
Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial
|
|
11 Jan 2021 |
ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer
|
|
11 Jan 2021 |
Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
|
|
07 Jan 2021 |
Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease
|
|
07 Jan 2021 |
REMD Biotherapeutics Completes Enrollment and Announces Top-line Results of a Phase 2 Clinical Study of Volagidemab (REMD-477) in Patients with Type 1 Diabetes
|
|
06 Jan 2021 |
Novel Treatment Pioneered by MSK Kids Researchers Receives FDA Approval for Patients with High-Risk Neuroblastoma
|
|
06 Jan 2021 |
Mersana Therapeutics Announces Corporate and Pipeline Updates and 2021 Goals and Anticipated Milestones
|
|
06 Jan 2021 |
Chemomab Announces Positive Phase Ib Results of its SPARK study testing CM-101 in NAFLD patients
|
|
06 Jan 2021 |
Y-Biologics signed License Agreement with 3D Medicines for T cell bispecific engager in Greater China territory
|
|
05 Jan 2021 |
Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients
|
|
05 Jan 2021 |
Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors
|
|
05 Jan 2021 |
F-star Therapeutics Announces First Patient Dosed in FS222 Phase 1 Clinical Trial
|
|
05 Jan 2021 |
Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
|
